Prometheus Biosciences to Present at 2021 RBC Capital Markets Global Healthcare Conference

Rhea-AI Summary

Prometheus Biosciences (Nasdaq: RXDX) announced Mark McKenna, President and CEO, will take part in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 19, 2021, at 10:55 a.m. ET. This San Diego-based clinical-stage biotechnology company focuses on precision medicine for immune-mediated diseases, particularly inflammatory bowel disease (IBD). The event will be accessible via live and archived webcasts on their website.

News Market Reaction – RXDX

+21.76%

+21.76% Session move

In the trading session that priced this news, RXDX gained 21.76%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bowel disease (IBD), today announced that Mark McKenna, President and CEO, will participate virtually in a fireside chat during the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 10:55 a.m. ET.

A live and archived webcast of the virtual fireside chat will be available via the Events section of the Prometheus Biosciences website.

About Prometheus Biosciences

Prometheus Biosciences, Inc. is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of immune-mediated diseases, starting first with IBD. The Company’s precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world’s largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets.  Prometheus is headquartered in San Diego, CA.

Contacts:
Noel Kurdi
VP Investor Relations and Communications
(646) 241-4400
nkurdi@prometheusbiosciences.com 

Media contact:
Juniper Point
Amy Conrad
(858) 914-1962
media@prometheusbiosciences.com 

FAQ

When is the Prometheus Biosciences fireside chat at the RBC Capital Markets Conference?

The fireside chat will take place on May 19, 2021, at 10:55 a.m. ET.

Who will represent Prometheus Biosciences at the 2021 RBC Conference?

Mark McKenna, President and CEO, will represent Prometheus Biosciences.

What is the main focus of Prometheus Biosciences?

Prometheus Biosciences focuses on precision medicine for immune-mediated diseases, starting with inflammatory bowel disease (IBD).

Where can I find the webcast of the fireside chat for Prometheus Biosciences?

The webcast will be available on the Events section of the Prometheus Biosciences website.

What is the stock symbol for Prometheus Biosciences?

The stock symbol for Prometheus Biosciences is RXDX.